Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand

Zimmer Biomet Holdings

05/08/2026 12:15

Aug 5 (Reuters) - Zimmer Biomet ZBH.N on Wednesday reported better-than-expected quarterly profit and sales and raised its full-year profit forecast, as demand for its devices used in orthopedic procedures stayed strong.
      Shares of the Warsaw, Indiana-based company rose over 5% in premarket trading. 

The medical device maker is in midst of a transition to a more dedicated and specialized U.S. sales channel, aiming to complete the majority of this transition by the end of 2027.
Revenue from the U.S., which represented about 58% of Zimmer's total net sales in 2025, rose 5.6% to $1.24 billion in the quarter ended June 30.
"We delivered strong second-quarter results with solid top- and bottom-line performance and continued progress on our key growth drivers and commercial transformation," said chief executive Ivan Tornos. 
Revenue from the hips business rose 5% to $562.7 million, while the knee business generated $828.9 million, up a modest 0.4%.
The unit that sells products for sports injuries and fractures increased 6.4% to $586 million.
Zimmer now anticipates full-year adjusted earnings of $8.47 to $8.59 per share, up from its previous forecast of $8.40 to $8.55. Analysts expects around $8.48 per share, according to LSEG data.
The company posted second-quarter revenue of $2.18 billion, up 4.8% from a year earlier, beating the $2.13 billion analysts had expected. Adjusted earnings were $2.07 per share, topping estimates of $2.01.

 (Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
 ((Kamal.Choudhury@thomsonreuters.com;))